Solitary pulmonary nodule — benign vs malignant, models and management viva

Interpretation

The examiner presents a CT image showing a single, well-defined rounded opacity in the lung, and asks: "What is this, how do you decide if it matters, and what would you do?"

• Definition (the gate question). This is a solitary pulmonary nodule (SPN) — a single, well-defined, roughly spherical opacity 3 cm or less in greatest diameter, surrounded by aerated lung, with no associated atelectasis, adenopathy, or pleural effusion. The size cut-off is absolute: a lesion over 3 cm is, by definition, a pulmonary MASS, presumed malignant until proven otherwise, and is investigated and staged as lung cancer.^[1]
• Why it matters. Most SPNs are benign (healed granuloma, hamartoma), but a minority are early, surgically curable lung cancer. The whole apparatus exists to catch the curable stage IA cancer (5-year survival over 80-90 percent when resected) without over-investigating the benign majority.^[1]

Key points

The examiner will probe each of these; be ready to defend them at viva depth:

1. The benign vs malignant radiographic features. Benign triad: smooth border + dense central/laminated/diffuse/'popcorn' calcification + no growth over 2 years (the stability rule). Malignant triad: spiculated or part-solid border + growth on serial CT + older smoker, often upper lobe. Name the four benign calcification patterns (central, laminated 'target', diffuse, 'popcorn' chondroid) versus the malignant-associated eccentric/stippled patterns.^[1]
2. The doubling-time rule and the 26 percent diameter rule. A malignant nodule doubles in volume every 30-400 days; under 30 days = infection/inflammation; over 400 days = benign (lepidic exceptions). Because volume scales with the cube of diameter, a 26 percent increase in diameter = a 100 percent (one doubling) increase in volume — never dismiss a small diameter rise.^[1]
3. The validated prediction models. Mayo/Swensen (1997) — six variables (age, smoking, extrathoracic cancer over 5 yr ago, diameter, spiculation, upper-lobe); thresholds under 5, 5-65, over 65 percent. Brock/PanCan (NEJM 2013) — the modern, best-performing model for screening-detected nodules; first-line in BTS 2015. Herder (2005) — Brock + PET uptake; the second step that reclassifies intermediate-risk nodules.^[2][3][4]
4. The BTS 2015 chain. Apply Brock → if over 10 percent, apply Herder → under 10 percent surveillance, 10-70 percent PET/biopsy, over 70 percent offer treatment.^[2][3]
5. Fleischner 2017 (incidental solid nodules). Under 6 mm = no follow-up; 6-8 mm = CT at 6-12 and 18-24 months; over 8 mm = consider CT/PET/biopsy at ~3 months. For subsolid nodules, key off the solid component; a part-solid nodule is the highest-risk morphology and a solid component of 6 mm or more is the lepidic-to-invasive threshold.^[1]
6. Tissue diagnosis — resect, don't biopsy, the high-risk nodule. If pre-test probability is high (over 65-85 percent) and the patient is fit, go straight to VATS wedge resection with frozen section, on to anatomic lobectomy with mediastinal node dissection if malignant. A pre-operative biopsy adds nothing and risks track seeding and pneumothorax. SBRT for the medically inoperable. TTNB (pneumothorax ~20 percent) and bronchoscopy/r-EBUS are for the intermediate-probability nodule.
7. Lung cancer screening — NLST (NEJM 2011). Three rounds of annual low-dose CT vs chest X-ray in heavy smokers gave a 20 percent reduction in lung-cancer mortality and 6.7 percent reduction in all-cause mortality. Screen adults 55-80 (USPSTF), 30 pack-years or more, quit within 15 years. Use Lung-RADS (not Fleischner) for screening nodules. The downside: ~96 percent of positive screens are not cancer (over-detection).^[6]
8. Regional delta (TB-endemic, e.g. India). High benign-granuloma prevalence depresses PET specificity (granulomas are FDG-avid); correlate with IGRA, send sputum AFB/Xpert MTB-RIF, and have a lower threshold for tissue with AFB and fungal stains before staging as cancer.^[1]

References

1. MacMahon H, et al. Fleischner Society 2017 guidelines for incidental pulmonary nodules. Radiology 2017.^[1]
2. McWilliams A, et al. Probability of cancer in pulmonary nodules (Brock/PanCan). NEJM 2013.^[2]
3. Herder GJ, et al. Clinical prediction model + PET (Herder model). Chest 2005.^[3]
4. Swensen SJ, et al. Probability of malignancy in solitary pulmonary nodules (Mayo). Arch Intern Med 1997.^[4]
5. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with LDCT. NEJM 2011.^[6]

References5ShowHide

1. [1]MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 2017.PMID 28240562
2. [2]McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT (PanCan / Brock model). New England Journal of Medicine, 2013.PMID 24004118
3. [3]Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-deoxyglucose positron emission tomography (Herder model). Chest, 2005.PMID 16236914
4. [4]Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules (Mayo Clinic model). Archives of Internal Medicine, 1997.PMID 9129544
5. [6]Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 2011.PMID 21714641